[Zolpidem (ivadal) treatment of sleep disorders].
|
| Abstract |
The results of the multicenter study of zolpidem activity, being carried out in inpatient- and out-patient clinics of 20 cities in Russia, are reported. One thousand seventeen patients with transitory, short time and chronic dyssomnia have been included in the trial. Zolpidem (ivadal, "Sanofi-Syntelabo", France) has been prescribed once a day in a dose of 10 mg (one tablet) before going to sleep in a period of two weeks. The efficiency has been assessed by evaluating dyssomnia symptoms according to "Sleep assessment questionnaire" of "Sanofi-Syntelabo" completed by the patients and "Clinical Global Impression Scale" completed by investigators. Safety has been assessed by analyzing a frequency of side effect appearance and changes in vital parameters: blood pressure, heart and breath rate. Zolpidem has been found to reveal high clinical efficiency and safety. By the end of the treatment, 59.5% of the patients experienced no difficulties in falling asleep, in 28.6% of the patients the latter being significantly reduced. On the whole the improvement was in 89.4% patients. No side effects have been observed. Zolpidem is a highly effective and safe medication for different type dyssomnia treatment that can be recommended for application in general clinical practice.
|
|---|---|
| Authors | Iu A Aleksandrovskiĭ, V V Androsova |
| Journal | Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova (Zh Nevrol Psikhiatr Im S S Korsakova) Vol. 101 Issue 9 Pg. 22-6 ( 2001) ISSN: 1997-7298 [Print] Russia (Federation) |
| Vernacular Title | Primenenie zolpidema (ivadala) pri lechenii narusheniĭ sna. |
| PMID | 11586699 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial) |
| Chemical References |
|
| Topics |
|
Join CureHunter, for free Research Interface BASIC access!
Realize the full power of the drug-disease research graph!